Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Splenectomy for hematologic disease.

P A Vevon1, E C Ellison, L C Carey

  • 1Department of Surgery, Ohio State University College of Medicine, Columbus.

Advances in Surgery
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Toward a Gender Neutral and Multicultural Meritocracy in Academic Surgery - No Better Time Than Now.

Annals of surgery·2020
Same author

Surgical safety checklist: Productive, nondisruptive, and the "right thing to do".

Journal of postgraduate medicine·2015
Same author

VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy.

The American surgeon·2004
Same author

Ontogeny of StAR and ACTH-R genes in ovine placenta.

Placenta·2004
Same journal

Total Pancreatectomy and Islet Cell Autotransplantation: Does It Have Long Lasting Benefits?

Advances in surgery·2025
Same journal

Clinical Decision-Making for Patients with Chronic Limb-Threatening Ischemia.

Advances in surgery·2025
Same journal

What Is the Role of Irreversible Electroporation for Pancreatic Cancer?

Advances in surgery·2025
Same journal

Airway Foreign Bodies in Children: Old Problem, New Advances.

Advances in surgery·2025
Same journal

Digestive Foreign Bodies in Children: Old Problems, New Complexities.

Advances in surgery·2025
Same journal

Management of Abdominal Wall Mesh Infections.

Advances in surgery·2025
See all related articles

Splenectomy removes the spleen to treat hematologic diseases by reducing red blood cell, white blood cell, and platelet destruction or sequestration. It offers palliative benefits and aids staging, though risks vary by condition.

Area of Science:

  • Hematology
  • Surgical Oncology

Background:

  • Splenectomy is a key treatment for various hematologic conditions.
  • It addresses erythrocyte, leukocyte, and platelet destruction or sequestration.
  • Indications include hemolytic anemia, immune thrombocytopenia (ITP), and symptomatic splenomegaly.

Purpose of the Study:

  • To review the role and indications of splenectomy in managing hematologic diseases.
  • To discuss its palliative and staging benefits.
  • To highlight considerations regarding patient selection and associated risks.

Main Methods:

  • Literature review of splenectomy's applications in hematologic disorders.
  • Analysis of its therapeutic and diagnostic utility.
  • Evaluation of safety profiles and risk factors.

Related Experiment Videos

Main Results:

  • Splenectomy effectively reduces cell destruction/sequestration in conditions like hemolytic anemia and ITP.
  • It provides palliative relief for splenomegaly in leukemia, lymphoma, and myeloproliferative disorders.
  • Splenectomy serves as a staging tool, particularly beneficial in Hodgkin's disease.

Conclusions:

  • Splenectomy is a valuable, though rarely curative, intervention in hematologic disease management.
  • It offers significant palliative and staging advantages.
  • Individualized patient assessment is crucial due to variable risks, especially in conditions like leukemia and lymphoma.